Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 22, 2024

Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Author(s)Robert O'Brien, RPh, Diana I. Brixner, PhD, RPh, Ashley Peterson, MHA

Medical experts identify key stakeholders within health plans who collaborate in the decision-making process for coverage, access, and benefit design related to prescription digital therapeutics.

Episodes in this series

Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"

EP. 1 Differentiating PDTs from Wellness Apps and Evaluating Efficacy

Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"

EP. 2 Payer Needs and Strategies for Evaluating and Covering PDTs

A panel of 4 experts on PDTs

EP. 3 Payers Review Process and Effective Strategies for PDT Coverage

A panel of 4 experts on PDTs

EP. 4 Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Video 5 - "Dawn of the Age of Adopting PDTs"

EP. 5 Dawn of the Age of Adopting PDTs

Video 6 -"Identifying the Most Impactful Disease Areas and Patient Populations for PDTs"

EP. 6 Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

4 KOLs discuss PDTs

EP. 7 Evolving Commercialization and Distribution Models for PDTs

4 KOLs discuss PDTs

EP. 8 Promoting Appropriate PDT Prescribing Through Provider Education and Support

A panel of 4 experts on PDTs

EP. 9 Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

A panel of 4 experts on PDTs

EP. 10 Optimizing Benefit Design and Implementation for Improved PDT Access

A panel of 4 experts on PDTs

EP. 11 PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

AJMC original research clinical

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Top view of red heart and medicine on wooden floor | Image credit: Jack Fotografo - stock.adobe.com

Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM

ByPearl Steinzor

June 3rd 2026

3D image of heart failure | Image credit: appledesign - stock.adobe.com

Sudden Death in HFpEF Often Preceded by Clinical Decline

ByPearl Steinzor

June 3rd 2026

Community Advanced Therapy Access Drives Equity: Fran Gregory, PharmD

ByLaura Joszt, MA,Fran Gregory, PharmD, MBA

June 3rd 2026

FDA website | Image credit: Tada Images - stock.adobe.com

FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301

ByGiuliana Grossi

June 3rd 2026

Trending on AJMC

How Often Do Health Insurers Deny Doctor-Recommended Care?

Sudden Death in HFpEF Often Preceded by Clinical Decline

New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor

Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM

What Managed Care Should Watch at ADA 2026 Scientific Sessions